Reproterol

Reproterol
Clinical data
AHFS/Drugs.com	International Drug Names
Routes of; administration	Inhalation (MDI), IV
ATC code	R03AC15 (WHO) ;
Legal status
Legal status	DE: § 48 AMG/§ 1 MPAV (Prescription only);
Identifiers
	IUPAC name (RS)-7-(3-{[2-(3,5-dihydroxyphenyl)-2-hydroxyethyl]amino}propyl)-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione;
CAS Number	54063-54-6 ;
PubChem CID	25654;
ChemSpider	23898 ;
UNII	11941YC6RN;
KEGG	D08474 ;
ChEMBL	ChEMBL1095607 ;
CompTox Dashboard (EPA)	DTXSID8023553 ;
ECHA InfoCard	100.053.579
Chemical and physical data
Formula	C18H23N5O5
Molar mass	389.412 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CCCNCC(C3=CC(=CC(=C3)O)O)O;
	InChI InChI=1S/C18H23N5O5/c1-21-16-15(17(27)22(2)18(21)28)23(10-20-16)5-3-4-19-9-14(26)11-6-12(24)8-13(25)7-11/h6-8,10,14,19,24-26H,3-5,9H2,1-2H3 ; Key:WVLAAKXASPCBGT-UHFFFAOYSA-N ;
	(what is this?) (verify)

Reproterol is a short-acting^[1] β₂ adrenoreceptor agonist used in the treatment of asthma.^[2]

It was patented in 1965 and came into medical use in 1977.^[3]

Stereochemistry

Reproterol contains a stereocenter and is chiral. There are thus two enantiomers, the (R)-form and the (S)-form. The commercial preparations contain the drug as a racemate, an equal mixture of the two enantiomers.^[4]

Enantiomers of reproterol
(R)-Reproterol CAS number: 210710-33-1	(S)-Reproterol CAS number: 210710-34-2

References

↑ Küpper T, Goebbels K, Kennes LN, Netzer NC (December 2012). "Cromoglycate, reproterol, or both--what's best for exercise-induced asthma?". Sleep & Breathing = Schlaf & Atmung. 16 (4): 1229–35. doi:10.1007/s11325-011-0638-2. PMID 22198635. S2CID 10032756.
↑ Virchow JC (1999). "Reproterol: beta-2-agonist, theophylline, or both?". Respiration; International Review of Thoracic Diseases. 66 (3): 210–1. doi:10.1159/000029379. PMID 10364735. S2CID 203732706.
↑ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 54X. ISBN 9783527607495.
↑ Rote Liste 2017 – Arzneimittelverzeichnis für Deutschland (einschließlich EU-Zulassungen und bestimmter Medizinprodukte). Vol. 57. Frankfurt/Main: Rote Liste Service GmbH. 2017. p. 196. ISBN 978-3-946057-10-9.

This article is issued from Wmcloud. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Küpper T, Goebbels K, Kennes LN, Netzer NC (December 2012). "Cromoglycate, reproterol, or both--what's best for exercise-induced asthma?". Sleep & Breathing = Schlaf & Atmung. 16 (4): 1229–35. doi:10.1007/s11325-011-0638-2. PMID 22198635. S2CID 10032756.

[pmid10364735-2] Virchow JC (1999). "Reproterol: beta-2-agonist, theophylline, or both?". Respiration; International Review of Thoracic Diseases. 66 (3): 210–1. doi:10.1159/000029379. PMID 10364735. S2CID 203732706.

[Fis2006-3] Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 54X. ISBN 9783527607495.

[Rote_Liste-4] Rote Liste 2017 – Arzneimittelverzeichnis für Deutschland (einschließlich EU-Zulassungen und bestimmter Medizinprodukte). Vol. 57. Frankfurt/Main: Rote Liste Service GmbH. 2017. p. 196. ISBN 978-3-946057-10-9.

[1]

[2]

[3]

[4]